SCHEMBL13633541

SCHEMBL13633541

COC(=O)c1ccnc(NS(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.61
TCF4 P15884 1/20 0.61
CTNNB1 P35222 1/20 0.61
ALDH1A1 P00352 7/20 0.59
KDM4E B2RXH2 6/20 0.59
ACLY P53396 1/20 0.58
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
HTT P42858 1/20 0.52
PKM P14618 1/20 0.49
POLB P06746 2/20 0.49
TSHR P16473 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
ALKBH2 Q6NS38 1/20 0.49
ALKBH5 Q6P6C2 1/20 0.49
ALKBH3 Q96Q83 1/20 0.49
FTO Q9C0B1 1/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13638237 0.86 ALKBH2 (0.64) ALDH1A1KDM4ELMNASMN1; SMN2HTT
SCHEMBL13749114 0.86 KDM4E (0.57) CYP2C9TCF4CTNNB1ALDH1A1KDM4E
SCHEMBL246879 0.80 ALDH1A1 (0.60) CYP2C9TCF4CTNNB1ALDH1A1KDM4E
SCHEMBL13633459 0.80 KDM4E (0.50) ALDH1A1KDM4ELMNASMN1; SMN2HTT
SCHEMBL13633502 0.80 KDM4E (0.50) ALDH1A1KDM4ELMNASMN1; SMN2HTT
SCHEMBL13633517 0.77 KDM4E (0.46) ALDH1A1KDM4ELMNASMN1; SMN2HTT
SCHEMBL1726830 0.77 ACLY (0.56) TCF4CTNNB1ALDH1A1KDM4EACLY
SCHEMBL7573928 0.77 CYP2C9 (0.82) CYP2C9TCF4CTNNB1ALDH1A1KDM4E
SCHEMBL21014027 0.77 ALDH1A1 (0.56) CYP2C9ALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL13633501 0.76 KDM4E (0.58) ALDH1A1KDM4ELMNASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS PFIZER INC 2009-11-05 US disclosed
US-7563788-B2 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents PFIZER INC. (US) 2009-07-21 US disclosed
US-7563788-B2 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents PFIZER INC. (US) 2009-07-21 US disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed
US-20070191394-A1 Antibacterial agents WARNER-LAMBERT COMPANY LLC 2007-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191394-A1 Antibacterial agents MRPL21, RPN2, FBL CYP2C9 557/4885TCF4 3959/4885CTNNB1 4639/4885
US-20090275577-A1 IMIDAZOPYRIDINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS DPYD, TYMP, ITPA CYP2C9 196/4885TCF4 3611/4885CTNNB1 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.